5[1]Zhang XW, Qing C, Xu B. Apoptosis induction and cell cycle perturbation in human hepatoma hep G2 cells by 10 hydroxycamptothecin. Anticancer Drugs,1999,10(6)∶569-576.
6[2]Lavergne D, Demarguay D, Bailly C, et al. Topoisomerase Ⅰ-mediated antiproliferative activity of enantiomerically pure fluorinated homocamptothecins. J Med Chem,2000,43(11)∶2285-2289.
7[6]Thongprasert S, Sanguanmitra P, Juthapan W, et al. Relationship between quality of life and clinical outcomes in advanced non-small cell lung cancer: best supportive care (BSC) versus BSC plus chemotherapy. Lung Cancer,1999,24(1)∶17-24.
8[7]Baldini E, Tibaldi C, Ardizzoni A, et al. Cisplatin-vindesine-mitomycin (MVP) vs cisplatin-ifosfamide-vinorelbine (PIN) vs carboplatin-vinorelbine (CaN) in patients with advanced non-small cell lung cancer (NSCLC): a FONICAP randomized phase Ⅱ study. Italian Lung Cancer Task Force (FONICAP). Br J Cancer,1998,77(12)∶2367-2370.
9[1]Langer CJ. Irinotecan/Taxane combinations in advanced non-small-cell lung cancer[J]. Clin Lung Cancer, 2002, (4 Supp l 1): S10-4.
10[2]Perez-Soler R, Fossella FV, Glisson BS, et al. Phase Ⅱ study of topotec an in patiens with advance non-small lung cancer previously untreated with chemotherapy[J]. J Clin Oncol, 1996, 14(2): 503-513.
